Are you checking for any specific mutations in NSCLC that suggest resistance to checkpoint inhibitors?
Are there any biomarkers that would affect your decision for first line PD-1 therapy (including but not limited to STK11)?
Answer from: Medical Oncologist at Community Practice
There has been a significant amount of data both published and presented concerning the various genomic markers (mutations) that may predict for response or the absence of response to immune checkpoint inhibitor. However, in clinical practice they are not commonly used as most patients are receiving...
Comments
Medical Oncologist at PINNACLE ONCOLOGY AND HEMATOLOGY Dr. Dowlati, thank you for the detailed response.&...
Dr. Dowlati, thank you for the detailed response.&...